[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:nasal-type-extranodal-nk-t-cell-lymphoma":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":41,"states":42},"Nasal Type Extranodal NK\u002FT-Cell Lymphoma",5,[7,15,22,29,35],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT02974647","Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma",[11],"Phase 2","RECRUITING","2026-08-26T02:18:38.865010Z","2026-05-05T02:43:28.499698Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT07382817","Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r\u002Fr CD94+ T\u002FNK Cell Neoplasms",[19],"Phase 1","2026-08-26T02:18:42.501841Z","2026-05-05T02:43:29.473779Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":27,"content_modified":28},"NCT03719105","Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia\u002FLymphoma",[26],"Early Phase 1","2026-08-26T02:17:44.240289Z","2026-05-05T02:43:28.474501Z",{"nct_id":30,"title":31,"phases":32,"status":12,"updated_at":33,"content_modified":34},"NCT05010005","A Study of Ruxolitinib and Duvelisib in People With Lymphoma",[19],"2026-08-26T02:16:01.079019Z","2026-05-05T02:43:26.685721Z",{"nct_id":36,"title":37,"phases":38,"status":12,"updated_at":39,"content_modified":40},"NCT05978141","A Registry for People With T-cell Lymphoma",[],"2026-08-26T02:16:20.336282Z","2026-05-13T02:55:06.403613Z",[],[43,47,51,54],{"state":44,"count":45,"slug":46},"New York",4,"new-york",{"state":48,"count":49,"slug":50},"Florida",3,"florida",{"state":52,"count":49,"slug":53},"Massachusetts","massachusetts",{"state":55,"count":49,"slug":56},"New Jersey","new-jersey"]